Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2021 | Aug. 10, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001595248 | |
Entity Registrant Name | Genprex, Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-38244 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 90-0772347 | |
Entity Address, Address Line One | 3300 Bee Cave Road, #650-227 | |
Entity Address, City or Town | Austin | |
Entity Address, State or Province | TX | |
Entity Address, Postal Zip Code | 78746 | |
City Area Code | 512 | |
Local Phone Number | 537-7997 | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | GNPX | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 47,527,857 |
Condensed Balance Sheets (Curre
Condensed Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 44,243,449 | $ 27,319,685 |
Accounts receivable | 127 | 127 |
Prepaid expenses and other | 755,596 | 384,553 |
Supplies | 3,062,357 | 3,011,042 |
Total current assets | 48,061,529 | 30,715,407 |
Property and equipment, net | 39,494 | 39,441 |
Other assets: | ||
Security deposits | 10,741 | 10,741 |
Intellectual property, net | 619,673 | 601,625 |
Total other assets | 630,414 | 612,366 |
Total assets | 48,731,437 | 31,367,214 |
Current liabilities: | ||
Accounts payable | 369,792 | 192,968 |
Other current liabilities | 677,427 | 257,756 |
Total current liabilities | 1,047,219 | 450,724 |
Stockholders’ equity: | ||
Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock $0.001 par value: 200,000,000 shares authorized; 47,522,857 and 43,117,681 shares issued and outstanding, respectively | 47,523 | 43,118 |
Additional paid-in capital | 116,534,756 | 89,295,601 |
Accumulated deficit | (68,898,060) | (58,422,229) |
Total stockholders’ equity | 47,684,218 | 30,916,490 |
Total liabilities and stockholders’ equity | $ 48,731,437 | $ 31,367,214 |
Condensed Balance Sheets (Cur_2
Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 47,522,857 | 43,117,681 |
Common stock, shares outstanding (in shares) | 47,522,857 | 43,117,681 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenues | $ 0 | $ 0 | $ 0 | $ 0 |
Cost and expenses: | ||||
Depreciation | 2,848 | 5,776 | 9,090 | 11,129 |
Research and development | 1,526,277 | 2,155,637 | 3,695,420 | 3,633,514 |
General and administrative | 2,458,097 | 2,216,691 | 6,774,407 | 6,309,687 |
Total costs and expenses | 3,987,222 | 4,378,104 | 10,478,917 | 9,954,330 |
Operating loss | (3,987,222) | (4,378,104) | (10,478,917) | (9,954,330) |
Interest income | 1,104 | 4,811 | 3,086 | 14,817 |
Net loss | $ (3,986,118) | $ (4,373,293) | $ (10,475,831) | $ (9,939,513) |
Net loss per share—basic and diluted (in dollars per share) | $ (0.08) | $ (0.12) | $ (0.23) | $ (0.31) |
Weighted average number of common shares— basic and diluted (in shares) | 47,372,490 | 35,358,058 | 46,464,343 | 31,655,400 |
Condensed Statements of Changes
Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2019 | 19,263,841 | |||
Balance at Dec. 31, 2019 | $ 19,264 | $ 43,483,740 | $ (40,479,459) | $ 3,023,545 |
Issuance of stock for cash (in shares) | 13,581,000 | |||
Issuance of stock for cash | $ 13,581 | 25,718,059 | 0 | 25,731,640 |
Issuance of stock for services (in shares) | 5,000 | |||
Issuance of stock for services | $ 5 | 1,545 | 0 | 1,550 |
Share based compensation | 0 | 752,444 | 0 | 752,444 |
Net loss | $ 0 | 0 | (5,566,220) | (5,566,220) |
Balance (in shares) at Mar. 31, 2020 | 32,849,841 | |||
Balance at Mar. 31, 2020 | $ 32,850 | 69,955,788 | (46,045,679) | 23,942,959 |
Balance (in shares) at Dec. 31, 2019 | 19,263,841 | |||
Balance at Dec. 31, 2019 | $ 19,264 | 43,483,740 | (40,479,459) | 3,023,545 |
Net loss | (9,939,513) | |||
Balance (in shares) at Jun. 30, 2020 | 38,629,229 | |||
Balance at Jun. 30, 2020 | $ 38,630 | 74,889,855 | (50,418,972) | 24,509,513 |
Balance (in shares) at Dec. 31, 2019 | 19,263,841 | |||
Balance at Dec. 31, 2019 | $ 19,264 | 43,483,740 | (40,479,459) | $ 3,023,545 |
Issuance of stock for cash (in shares) | 5,511,599 | |||
Issuance of stock for services (in shares) | 51,432 | |||
Issuance of stock for services | $ 154,648 | |||
Balance (in shares) at Dec. 31, 2020 | 43,117,681 | |||
Balance at Dec. 31, 2020 | $ 43,118 | 89,295,601 | (58,422,229) | 30,916,490 |
Balance (in shares) at Mar. 31, 2020 | 32,849,841 | |||
Balance at Mar. 31, 2020 | $ 32,850 | 69,955,788 | (46,045,679) | 23,942,959 |
Issuance of stock for cash (in shares) | 5,658,836 | |||
Issuance of stock for cash | $ 5,659 | 2,563,567 | 0 | 2,569,226 |
Issuance of stock for services (in shares) | 120,552 | |||
Issuance of stock for services | $ 121 | 10,879 | 0 | 11,000 |
Share based compensation | 0 | 2,359,621 | 0 | 2,359,621 |
Net loss | $ 0 | 0 | (4,373,293) | (4,373,293) |
Balance (in shares) at Jun. 30, 2020 | 38,629,229 | |||
Balance at Jun. 30, 2020 | $ 38,630 | 74,889,855 | (50,418,972) | 24,509,513 |
Balance (in shares) at Dec. 31, 2020 | 43,117,681 | |||
Balance at Dec. 31, 2020 | $ 43,118 | 89,295,601 | (58,422,229) | 30,916,490 |
Issuance of stock for cash (in shares) | 4,192,139 | |||
Issuance of stock for cash | $ 4,192 | 25,320,138 | 0 | 25,324,330 |
Issuance of stock for services (in shares) | 5,000 | |||
Issuance of stock for services | $ 5 | 20,645 | 0 | 20,650 |
Share based compensation | 0 | 651,088 | 0 | 651,088 |
Net loss | $ 0 | 0 | (6,489,714) | (6,489,714) |
Balance (in shares) at Mar. 31, 2021 | 47,314,820 | |||
Balance at Mar. 31, 2021 | $ 47,315 | 115,287,472 | (64,911,943) | 50,422,845 |
Balance (in shares) at Dec. 31, 2020 | 43,117,681 | |||
Balance at Dec. 31, 2020 | $ 43,118 | 89,295,601 | (58,422,229) | $ 30,916,490 |
Issuance of stock for cash (in shares) | 10,000 | |||
Issuance of stock for services | $ 41,750 | |||
Net loss | (10,475,831) | |||
Balance (in shares) at Jun. 30, 2021 | 47,522,857 | |||
Balance at Jun. 30, 2021 | $ 47,523 | 116,534,756 | (68,898,060) | 47,684,218 |
Balance (in shares) at Mar. 31, 2021 | 47,314,820 | |||
Balance at Mar. 31, 2021 | $ 47,315 | 115,287,472 | (64,911,943) | 50,422,845 |
Issuance of stock for cash (in shares) | 203,037 | |||
Issuance of stock for cash | $ 203 | 109,830 | 0 | 110,033 |
Issuance of stock for services (in shares) | 5,000 | |||
Issuance of stock for services | $ 5 | 21,095 | 0 | 21,100 |
Share based compensation | 0 | 1,116,359 | 0 | 1,116,358 |
Net loss | $ 0 | 0 | (3,986,118) | (3,986,118) |
Balance (in shares) at Jun. 30, 2021 | 47,522,857 | |||
Balance at Jun. 30, 2021 | $ 47,523 | $ 116,534,756 | $ (68,898,060) | $ 47,684,218 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Cash flows from operating activities: | |||||||
Net loss | $ (3,986,118) | $ (6,489,714) | $ (4,373,293) | $ (5,566,220) | $ (10,475,831) | $ (9,939,513) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Depreciation | 2,848 | 5,776 | 9,090 | 11,129 | |||
Share based compensation | 1,809,196 | 3,124,615 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | 0 | 570 | |||||
Prepaid expenses and other | (371,043) | (953,778) | |||||
Accounts payable and accrued expenses | 176,824 | (254,291) | |||||
Other current liabilities | 419,671 | (16,607) | |||||
Net cash used in operating activities | (8,432,093) | (8,027,875) | |||||
Cash flows from investing activities: | |||||||
Additions to property and equipment | (9,142) | (12,762) | |||||
Additions to intellectual property | (18,048) | (43,323) | |||||
Additions to research and development supplies | (51,315) | (92,219) | |||||
Net cash used in investing activities | (78,505) | (148,304) | |||||
Cash flows from financing activities: | |||||||
Proceeds from issuances of stock | 25,434,363 | 28,300,866 | |||||
Net cash provided by financing activities | 25,434,363 | 28,300,866 | |||||
Net increase in cash and cash equivalents | 16,923,765 | 20,124,687 | |||||
Cash and cash equivalents, beginning of period | $ 27,319,684 | $ 2,002,492 | 27,319,684 | 2,002,492 | $ 2,002,492 | ||
Cash and cash equivalents, end of period | $ 44,243,449 | $ 22,127,179 | 44,243,449 | 22,127,179 | $ 27,319,684 | ||
Supplemental Disclosure of Cash Flow Information | |||||||
Cash paid for interest | 0 | 0 | |||||
Cash paid for taxes | $ 0 | $ 0 |
Note 1 - Description of Busines
Note 1 - Description of Business and Basis of Presentation | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1 We are a clinical stage gene therapy company focused on developing life-changing treatments for cancer and diabetes. Our lead cancer drug candidate, REQORSA™ Immunogene therapy drug (sometimes referred to as GPX- 001 , TUSC2 TUSC2 TUSC2 TUSC2 one Our Acclaim- 1 1/2 January 2020, 1 June 2021, 1 first 1 1 no fourth 2021. Our Acclaim- 2 1/2 2 2021. In diabetes, we are developing a gene therapy that is exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education ("University of Pittsburgh") for the treatment of Type 1 2 Oncology Platform Utilizing our non-viral ONCOPREX Nanoparticle Delivery System, we are developing cancer treatments that are designed to administer cancer fighting genes. We encapsulate the gene-expressing plasmids using ONCOPREX lipid nanoparticles, and administer them intravenously, where they are then taken up by tumor cells and express proteins that are missing or found in low quantities in the tumor cells. With our lead drug candidate, REQORSA, there is a multimodal mechanism of action whereby REQORSA interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. We believe that our ONCOPREX Nanoparticle Delivery System could allow delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer. We believe that REQORSA’s combination of pan-kinase inhibition, direct induction of apoptosis, anti-cancer immune modulation and complementary action with targeted drugs and immunotherapies is unique, and positions REQORSA to provide treatment for patients with NSCLC and possibly other cancers, who are not Diabetes Gene Therapy Our diabetes gene therapy, also referred to as GPX- 002, Pdx1 Capital Requirements, Liquidity and Going Concern Considerations Our unaudited condensed financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying unaudited condensed financial statements, we have sustained substantial losses from operations since inception and have no Management recognizes that we must obtain additional capital resources to successfully commercialize our product candidates. To date, we have received funding in the form of equity and debt, and we plan to seek additional funding in the future. However, no not may not |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2 The Company’s unaudited condensed financial statements have been prepared in accordance with GAAP. However, they do not not three six June 30, 2021 not may December 31, 2021 December 31, 2020 10 March 26, 2021. Capital Stock In connection with the Company’s initial public offering ("IPO") in April 2018, 1. Use of Estimates The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We consider all highly liquid short-term investments with an initial maturity of three $250,000 June 30, 2021 December 31, 2020 Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Accounting Standards Codification ("ASC") 820, 820’s 820 Level 1: Level 2: not Level 3: Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five Research and Development Costs Research and development expenditures consist of costs incurred to conduct research and development activities. These include payments to collaborative research partners, manufacturing partners, and clinical strategy partners, wages and associated employee benefits, facilities and overhead costs. These expenditures relate to our preclinical and Phase 1/2 June 30, 2021 December 31, 2020 Awards In 2010, two 2010 2011. March 2014 August 15, 2019. In 2010, 2011 no Intellectual Property Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not six June 30, 2021 December 31, 2020 Recent Accounting Developments Accounting pronouncements issued but not June 30, 2021 not |
Note 3 - Intellectual Property
Note 3 - Intellectual Property | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Intangible Assets Disclosure [Text Block] | Note 3 On February 11, 2020, 1 2 On May 4, 2020, 16 We have exclusive license agreements on 28 18 three June 30, 2021, one 18 |
Note 4 - Equity
Note 4 - Equity | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 4 Registered Direct Offerings On January 21, 2020, On January 23, 2020, On February 19, 2020, 3 February 21, 2020, 3 On December 24, 2020, On February 10, 2021, Stock Issuances During the six June 30, 2021 During the year ended December 31, 2020 Preferred Stock In connection with the Company’s IPO, all preferred stock included in Series A through Series G preferred stock, totaling 1,394,953 shares were converted to an aggregate of 9,324,177 shares of the Company's common stock in connection with the forward-split (See Note 2 June 30, 2021 Common Stock Upon the completion of the IPO, all of the Company’s non-voting common stock automatically converted into voting common stock on a one-for- one June 30, 2021 Common Stock Purchase Warrants Common stock purchase warrant activity for the period and year ended June 30, 2021 December 31, 2020 Number of Weighted Average Warrants Exercise Price Outstanding at January 1, 2020 7,476,056 $ 1.45 Issued 550,000 2.41 Cancelled or expired (44,528 ) 0.50 Exercised (5,826,781 ) 0.47 Outstanding at December 31, 2020 2,154,747 $ 4.37 Issued 25,000 7.22 Cancelled or expired — — Exercised — — Outstanding at June 30, 2021 2,179,747 $ 4.40 Vested or expected to vest at June 30, 2021 — — Exercisable at June 30, 2021 1,929,747 $ 4.64 During the six June 30, 2021 six June 30, 2021 During the year ended December 31, 2020, ( May 2018 November 2019 November 2019 December 31, 2020, three On January 29, 2018, June 30, 2021 not 2018 The Company’s board of directors and stockholders approved and adopted the Company’s 2018 “2018 April 3, 2018. 2018 may may A total of 4,160,000 shares of common stock were originally reserved for issuance under the 2018 2009 2018 No 2009 no 2009 2009 2009 2018 In addition, the number of shares of common stock reserved for issuance under the 2018 January 1 January 1, 2019, December 31 2018 January 1, 2020, 2021, 2018 June 30, 2021, 1,820,6310 2018 2018 The Company’s board of directors and stockholders approved and adopted the Company’s 2018 April 3, 2018. not may January 1 January 1, 2019, December 31 not January 1, 2021 Stock Options As of June 30, 2021 ten Expected term (in years): 10 Risk-free rate: 0.07% – 2.63% Volatility: 75.98% – 87.55% Dividend yield: 0% During the six June 30, 2021 During the year ending December 31, 2020, The weighted average remaining contractual term for the outstanding options at June 30, 2021 December 31, 2020 Stock option activity for the six June 30, 2021 December 31, 2020 Number of Weighted Average Shares Exercise Price Outstanding at January 1, 2020 5,982,923 $ 2.66 Options granted 2,466,529 2.87 Options exercised (1,277,743 ) 1.03 Options expired (327,640 ) 8.31 Outstanding at December 31, 2020 6,844,069 $ 2.81 Options granted 1,499,628 6.01 Options exercised (395,176 ) 1.10 Options expired or cancelled (10,000 ) 7.22 Outstanding at June 30, 2021 7,938,521 $ 3.34 Vested or expected to vest at June 30, 2021 443,535 2.99 Exercisable at June 30, 2021 4,820,913 $ 2.97 Share-Based Compensation For the six June 30, 2021 not three June 30, 2021 three June 30, 2021 As of June 30, 2021 not may |
Note 5 - Related Party Transact
Note 5 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 5 Introgen Research Institute Introgen Research Institute (“IRI”) is a Texas-based technology company, currently affiliated with Rodney Varner, our President, Chief Executive Officer, and director. In April 2009, August 2012, 2011 Viet Ly The Company entered into a consulting agreement with Viet Ly, an advisor to the Company, on April 19, 2018. three June 30, 2021 April 2020, February 10, 2021, 12 February 2022. |
Note 6 - Commitments and Contin
Note 6 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 6 Leases On April 16, 2018, March 23, 2021, not April 30, 2021. On April 16, 2018, April 1, 2020, April 30, 2020. Commitments MD Anderson Cancer Center The Company entered into a clinical study agreement with the MD Anderson, to administer the Company’s phase 1/2 4 2018 may 2020, 1 no 002 June 2021, 1 2 2021. July 2018, two may May 2022. In 2011, 1994 On March 3, 2021, May 4, 2020, six one TUSC2 TUSC2 five six one five National Institutes of Health Our $191,393 payment obligation to the National Institutes of Health (“NIH”) represented a current obligation, of which $15,393 of 2016 fourth 2016 December 31, 2016 ( first 2017, 2018, second 2017. As a result of our modified agreement with the NIH, we have recognized the exchange of the $120,000 $240,000 first 2017. $240,000 $20,000 December 31, 2020, University of Pittsburgh Pursuant to the Exclusive License Agreement dated February 11, 2020 first three first first 20 first Contingencies From time to time, we may not |
Note 7 - Significant Events
Note 7 - Significant Events | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Effect of Covid 19 Pandemic [Text Block] | Note 7 In March 2020, 19 may 19 not 19, March 31, 2021, not 19 three June 30, 2021, 19 |
Note 8 - Subsequent Events
Note 8 - Subsequent Events | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 8 Share Issuance On July 1, 2021, Warrant Issuance On July 1, 2021, Option Issuance On July 12, 2021, 2018 Intellectual Property Subsequent to June 30, 2021, two 18 28 13 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Stockholders' Equity, Policy [Policy Text Block] | Capital Stock In connection with the Company’s initial public offering ("IPO") in April 2018, 1. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of our unaudited condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents We consider all highly liquid short-term investments with an initial maturity of three $250,000 June 30, 2021 December 31, 2020 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The carrying amounts reported in the balance sheet for cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Accounting Standards Codification ("ASC") 820, 820’s 820 Level 1: Level 2: not Level 3: |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Furniture and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three five |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs Research and development expenditures consist of costs incurred to conduct research and development activities. These include payments to collaborative research partners, manufacturing partners, and clinical strategy partners, wages and associated employee benefits, facilities and overhead costs. These expenditures relate to our preclinical and Phase 1/2 June 30, 2021 December 31, 2020 |
Awards [Policy Text Block] | Awards In 2010, two 2010 2011. March 2014 August 15, 2019. In 2010, 2011 no |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Intellectual Property Intellectual property consists of legal and related costs associated with patents and other proprietary technology and rights developed, acquired, licensed by, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These costs incurred in connection with obtaining and maintaining intellectual property protection, such as patent applications and patent maintenance, are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. |
Share-based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation We use the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors. We measure options granted at fair value determined as of the grant date and recognize the expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not six June 30, 2021 December 31, 2020 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Developments Accounting pronouncements issued but not June 30, 2021 not |
Note 4 - Equity (Tables)
Note 4 - Equity (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Weighted Average Warrants Exercise Price Outstanding at January 1, 2020 7,476,056 $ 1.45 Issued 550,000 2.41 Cancelled or expired (44,528 ) 0.50 Exercised (5,826,781 ) 0.47 Outstanding at December 31, 2020 2,154,747 $ 4.37 Issued 25,000 7.22 Cancelled or expired — — Exercised — — Outstanding at June 30, 2021 2,179,747 $ 4.40 Vested or expected to vest at June 30, 2021 — — Exercisable at June 30, 2021 1,929,747 $ 4.64 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Expected term (in years): 10 Risk-free rate: 0.07% – 2.63% Volatility: 75.98% – 87.55% Dividend yield: 0% |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Number of Weighted Average Shares Exercise Price Outstanding at January 1, 2020 5,982,923 $ 2.66 Options granted 2,466,529 2.87 Options exercised (1,277,743 ) 1.03 Options expired (327,640 ) 8.31 Outstanding at December 31, 2020 6,844,069 $ 2.81 Options granted 1,499,628 6.01 Options exercised (395,176 ) 1.10 Options expired or cancelled (10,000 ) 7.22 Outstanding at June 30, 2021 7,938,521 $ 3.34 Vested or expected to vest at June 30, 2021 443,535 2.99 Exercisable at June 30, 2021 4,820,913 $ 2.97 |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Apr. 03, 2018$ / sharesshares | Mar. 31, 2018$ / sharesshares | Mar. 31, 2014shares | Jun. 30, 2021USD ($)$ / sharesshares | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($)$ / sharesshares | Jun. 30, 2020USD ($) | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2011USD ($) | Dec. 31, 2010USD ($) |
Stockholders' Equity Note, Stock Split, Conversion Ratio | 6.6841954 | |||||||||
Capital Stock, Shares Authorized (in shares) | shares | 210,000,000 | |||||||||
Common Stock, Shares Authorized (in shares) | shares | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | |||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||
Preferred Stock, Shares Authorized (in shares) | shares | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | |||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||
Cash, Uninsured Amount | $ 43,990,330 | $ 43,990,330 | $ 27,091,596 | |||||||
Research and Development Assets, Current | 3,062,357 | 3,062,357 | 3,011,042 | |||||||
State of Texas Emerging Technology Fund Award Amount | $ 4,500,000 | |||||||||
Proceeds from State of Texas Emerging Technology Fund Award | $ 2,250,000 | 2,250,000 | ||||||||
Revenues, Total | $ 0 | $ 0 | 0 | $ 0 | ||||||
Impairment of Long-Lived Assets Held-for-use | $ 0 | $ 0 | ||||||||
Grant [Member] | U.S. Treasury Department [Member] | ||||||||||
Revenues, Total | $ 244,500 | |||||||||
Conversion of Preferred Stock to Common Stock [Member] | ||||||||||
Conversion of Stock, Shares Issued (in shares) | shares | 9,324,177 | 1,235,219 | ||||||||
Minimum [Member] | ||||||||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |||||||||
Maximum [Member] | ||||||||||
Property, Plant and Equipment, Useful Life (Year) | 5 years |
Note 4 - Equity (Details Textua
Note 4 - Equity (Details Textual) | Feb. 10, 2021USD ($)$ / sharesshares | Jan. 01, 2021shares | Dec. 24, 2020USD ($)$ / sharesshares | Feb. 21, 2020USD ($)$ / sharesshares | Feb. 19, 2020USD ($) | Jan. 23, 2020USD ($)$ / sharesshares | Jan. 21, 2020USD ($)$ / sharesshares | Jan. 01, 2020shares | Mar. 31, 2018$ / sharesshares | Mar. 31, 2014shares | Jun. 30, 2021USD ($)$ / sharesshares | Mar. 31, 2021USD ($) | Jun. 30, 2020USD ($) | Mar. 31, 2020USD ($) | Jun. 30, 2021USD ($)$ / sharesshares | Jun. 30, 2020USD ($) | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 30, 2020USD ($)shares | Apr. 30, 2020$ / sharesshares | Dec. 31, 2019$ / sharesshares | Apr. 03, 2018$ / sharesshares | Jan. 29, 2018USD ($)$ / sharesshares |
Stock Issued During Period, Shares, New Issues (in shares) | 10,000 | 5,511,599 | ||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 25,434,363 | $ 28,300,866 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 395,176 | 1,277,743 | ||||||||||||||||||||
Stock Issued During Period, Value, Stock Options Exercised | $ | $ 435,031 | $ 1,320,155 | ||||||||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ | $ 21,100 | $ 20,650 | $ 11,000 | $ 1,550 | $ 41,750 | 154,648 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 2,537,731 | |||||||||||||||||||||
Stock Issued During Period, Shares, Exercise of Cashless Warrants (in shares) | 199,630 | |||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 51,432 | |||||||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | |||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 0 | |||||||||||||||||||
Non-voting To Voting Common Stock, Conversion Ratio | 1 | |||||||||||||||||||||
Common Stock, Shares Authorized (in shares) | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | 200,000,000 | |||||||||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||
Common Stock, Shares, Outstanding, Ending Balance (in shares) | 47,522,857 | 47,522,857 | 43,117,681 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 315,182 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 4.40 | $ 4.40 | $ 4.37 | $ 1.45 | ||||||||||||||||||
Stock Issued During Period, Shares, Warrants Issued (in shares) | 5,511,599 | |||||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 2,537,731 | |||||||||||||||||||||
Class of Warrant or Right, Issued in Period (in shares) | 25,000 | 550,000 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 7,938,521 | 7,938,521 | 6,844,069 | 5,982,923 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ / shares | $ 3.34 | $ 3.34 | $ 2.81 | $ 2.66 | ||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 1,499,628 | 2,466,529 | ||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 6.01 | $ 2.87 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares) | 10,000 | 327,640 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 7.22 | $ 8.31 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 7 years 8 months 8 days | 7 years 21 days | ||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 2,179,747 | 2,179,747 | 2,154,747 | 7,476,056 | ||||||||||||||||||
Minimum [Member] | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.02 | $ 0.02 | $ 0.015 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 12 months | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ / shares | 0.001 | $ 0.001 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | 0.001 | |||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | 3.55 | 1.28 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | 5.29 | |||||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | 2.15 | $ 2.15 | 2.15 | |||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) | 48 months | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ / shares | $ 9.80 | $ 9.80 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | 7.93 | |||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 7.22 | 4.42 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 9.80 | |||||||||||||||||||||
The 2018 Equity Incentive Plan [Member] | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 1,820,631 | 1,820,631 | 4,160,000 | |||||||||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 5.00% | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 2,155,884 | 963,192 | ||||||||||||||||||||
The 2009 Plan [Member] | ||||||||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 554,963 | |||||||||||||||||||||
The 2018 Employee Stock Purchase Plan [Member] | ||||||||||||||||||||||
Share Based Compensation Arrangement By Share Based Payment Award, Percentage Applied on Outstanding Shares of Common Stock For Automatically Increase on Each Year | 2.00% | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 208,500 | |||||||||||||||||||||
Time Based Options [Member] | ||||||||||||||||||||||
Share-based Payment Arrangement, Expense, Future Milestone | $ | $ 124,000 | |||||||||||||||||||||
Performance Shares [Member] | ||||||||||||||||||||||
Share-based Payment Arrangement, Expense, Future Milestone | $ | 300,000 | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 0 | 0 | ||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | ||||||||||||||||||||||
Share-based Payment Arrangement, Expense | $ | $ 1,800,000 | |||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ | $ 8,400,000 | $ 8,400,000 | ||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 3 years | |||||||||||||||||||||
Share-based Payment Arrangement, Option [Member] | Graded Vesting Method [Member] | ||||||||||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 1 month 20 days | |||||||||||||||||||||
Bear Creek Capital Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 25,000 | 25,000 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 7.22 | $ 7.22 | ||||||||||||||||||||
Share-based Payment Arrangement, Expense | $ | $ 115,628 | |||||||||||||||||||||
Warrants Issued for Services [Member] | ||||||||||||||||||||||
Share-based Payment Arrangement, Expense | $ | $ 450,000 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 550,000 | |||||||||||||||||||||
Warrants Issued to Cancer Revolution LLC, an entity owned by Viet Ly [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 500,000 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 2.27 | $ 2.27 | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 500,000 | |||||||||||||||||||||
Warrants Issued to Capital City Technical Consulting Inc [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 3.81 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 50,000 | |||||||||||||||||||||
Performance-based Warrant [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1 | 1 | ||||||||||||||||||||
Warrant, Nonvested Award, Cost Not yet Recognized, Amount | $ | $ 300,000 | $ 300,000 | ||||||||||||||||||||
Conversion of Preferred Stock to Common Stock [Member] | ||||||||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,394,953 | |||||||||||||||||||||
Conversion of Stock, Shares Issued (in shares) | 9,324,177 | 1,235,219 | ||||||||||||||||||||
FundAthena, Inc [Member] | Warrants Issued for Services [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,000 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | |||||||||||||||||||||
Accounts Payable, Total | $ | $ 30,000 | |||||||||||||||||||||
Class of Warrant or Right, Issued in Period (in shares) | 0 | |||||||||||||||||||||
Registered Direct Offering [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 4,000,000 | 16,697,884 | ||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 25,000,000 | $ 37,731,643 | ||||||||||||||||||||
Registered Direct Offerings, Maximum Offering Size, Increase | $ | $ 3,000,000 | |||||||||||||||||||||
Registered Direct Offering [Member] | Accredited Investor [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,116,884 | 961,000 | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 3.85 | $ 0.24 | ||||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 11,200,000 | $ 200,000 | ||||||||||||||||||||
Registered Direct Offering [Member] | Investors [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 4,000,000 | 5,000,000 | 7,620,000 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 6.25 | $ 3.50 | $ 1.05 | |||||||||||||||||||
Proceeds from Issuance of Common Stock | $ | $ 23,200,000 | $ 16,000,000 | $ 7,200,000 |
Note 4 - Equity - Common Stock
Note 4 - Equity - Common Stock Purchase Warrant Activity (Details) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Outstanding, number of warrants (in shares) | 2,154,747 | 7,476,056 |
Outstanding, weighted average exercise price (in dollars per share) | $ 4.37 | $ 1.45 |
Issued, number of warrants (in shares) | 25,000 | 550,000 |
Issued, weighted average exercise price (in dollars per share) | $ 7.22 | $ 2.41 |
Cancelled or expired, number of warrants (in shares) | 0 | (44,528) |
Cancelled or expired, weighted average exercise price (in dollars per share) | $ 0 | $ 0.50 |
Exercised, number of warrants (in shares) | 0 | (5,826,781) |
Exercised, weighted average exercise price (in dollars per share) | $ 0 | $ 0.47 |
Outstanding, number of warrants (in shares) | 2,179,747 | 2,154,747 |
Outstanding, weighted average exercise price (in dollars per share) | $ 4.40 | $ 4.37 |
Vested or expected to vest, number of warrants (in shares) | 0 | |
Vested or expected to vest, weighted average exercise price (in dollars per share) | $ 0 | |
Exercisable, number of warrants (in shares) | 1,929,747 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 4.64 |
Note 4 - Equity - Assumptions (
Note 4 - Equity - Assumptions (Details) | 6 Months Ended |
Jun. 30, 2021 | |
Expected term (in years): (Year) | 10 years |
Dividend yield: | 0.00% |
Minimum [Member] | |
Risk-free rate: | 0.07% |
Volatility: | 75.98% |
Maximum [Member] | |
Risk-free rate: | 2.63% |
Volatility: | 87.55% |
Note 4 - Equity - Stock Option
Note 4 - Equity - Stock Option Activity (Details) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2021 | Dec. 31, 2020 | |
Outstanding, number of shares (in shares) | 6,844,069 | 5,982,923 |
Outstanding, weighted average exercise price (in dollars per share) | $ 2.81 | $ 2.66 |
Options granted, number of shares (in shares) | 1,499,628 | 2,466,529 |
Options granted, weighted average exercise price (in dollars per share) | $ 6.01 | $ 2.87 |
Options exercised, number of shares (in shares) | (395,176) | (1,277,743) |
Options exercised, weighted average exercise price (in dollars per share) | $ 1.10 | $ 1.03 |
Options expired (in shares) | (10,000) | (327,640) |
Options expired, weighted average exercise price (in dollars per share) | $ 7.22 | $ 8.31 |
Outstanding, number of shares (in shares) | 7,938,521 | 6,844,069 |
Outstanding, weighted average exercise price (in dollars per share) | $ 3.34 | $ 2.81 |
Vested or expected to vest, number of shares (in shares) | 443,535 | |
Vested or expected to vest, weighted average exercise price (in dollars per share) | $ 2.99 | |
Exercisable, number of shares (in shares) | 4,820,913 | |
Exercisable, weighted average exercise price (in dollars per share) | $ 2.97 |
Note 5 - Related Party Transa_2
Note 5 - Related Party Transactions (Details Textual) - USD ($) | Feb. 10, 2021 | Jun. 30, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | Apr. 30, 2020 | Dec. 31, 2019 | Apr. 19, 2018 |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 315,182 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4.40 | $ 4.40 | $ 4.37 | $ 1.45 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 1,499,628 | 2,466,529 | |||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 6.01 | $ 2.87 | |||||
Warrants Issued to Cancer Revolution LLC, an entity owned by Viet Ly [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 500,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.27 | $ 2.27 | |||||
Viet Ly [Member] | |||||||
Related Party, Initial Annual Consulting Compensation to be Paid | $ 175,000 | ||||||
Related Party, Consulting Compensation, Aggregate Amount | $ 28,500 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 100,000 | ||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 7.72 |
Note 6 - Commitments and Cont_2
Note 6 - Commitments and Contingencies (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
Jul. 31, 2018 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2018 | Dec. 31, 2016 | Dec. 31, 2009 | Mar. 03, 2021 | Dec. 31, 2020 | Feb. 11, 2020 | |
Payments to Acquire Intangible Assets | $ 18,048 | $ 43,323 | ||||||||||
License Agreement Terms [Member] | ||||||||||||
License Agreement Milestone Payment | $ 6,150,000 | |||||||||||
National Institute of Health [Member] | ||||||||||||
Royalty on Sales, Percentage | 1.00% | |||||||||||
Royalty Term (Year) | 21 years | |||||||||||
Royalty Payment, Annual Minimum | $ 20,000 | |||||||||||
Other Commitment, Total | $ 191,393 | $ 191,393 | $ 300,000 | |||||||||
Legal Fees | 15,393 | |||||||||||
Accounts Payable, Other, Current | 176,000 | 176,000 | ||||||||||
Accrued Royalties, Current | $ 140,000 | 140,000 | ||||||||||
Other Expenses, Total | $ 36,000 | |||||||||||
Extinguishment of Debt, Amount | $ 120,000 | |||||||||||
Accrued Patent Costs, Current | 36,000 | |||||||||||
Payments for Royalties | $ 20,000 | 20,000 | ||||||||||
Payment for Contingent Consideration Liability, Operating Activities | 240,000 | |||||||||||
Contingent Payments Annual Increase | 20,000 | |||||||||||
Payments to Acquire Intangible Assets | $ 36,000 | |||||||||||
Finite-Lived Intangible Assets, Period Increase (Decrease), Total | $ (120,000) | |||||||||||
Clinical Trial Agreement [Member] | MD Anderson [Member] | ||||||||||||
Long Term Contract, Estimated Cost | $ 2,000,000 | |||||||||||
Research Agreement [Member] | MD Anderson [Member] | ||||||||||||
Long Term Contract, Estimated Cost | $ 2,000,000 | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | ||||||||||||
Licensing Fee, Amount | $ 25,000 | |||||||||||
Annual Maintenance Fee, First Three Years, Amount | 25,000 | |||||||||||
Annual Maintenance Fee, After Year Three, Amount | 40,000 | |||||||||||
Annual Royalty Payment Per Year, Minimum | $ 250,000 | |||||||||||
Share of Non-Royalty Sublicense Income, Percent | 20.00% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Dosing of First Human Patient in a Phase I Clinical Trial [Member] | ||||||||||||
Milestone Payment | $ 3,975,000 | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Minimum [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 1.50% | |||||||||||
License Agreement [Member] | University of Pittsburgh [Member] | Maximum [Member] | ||||||||||||
Royalty Percent, Licensed Technology Covered by Patent | 3.00% |
Note 8 - Subsequent Events (Det
Note 8 - Subsequent Events (Details Textual) - $ / shares | Jul. 12, 2021 | Jul. 01, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Stock Issued During Period, Shares, Issued for Services (in shares) | 51,432 | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 315,182 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 4.40 | $ 4.37 | $ 1.45 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 1,499,628 | 2,466,529 | |||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 6.01 | $ 2.87 | |||
Subsequent Event [Member] | |||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 5,000 | ||||
Subsequent Event [Member] | The 2018 Equity Incentive Plan [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 17,500 | ||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 3.14 | ||||
Subsequent Event [Member] | Consultant Warrants [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 25,000 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.36 |